
AZD-5153
CAS No. 1869912-39-9
AZD-5153 ( AZD5153 )
产品货号. M12890 CAS No. 1869912-39-9
AZD-5153 是一种有效、选择性、二价、口服的 BET/BRD4 溴结构域,IC50 为 5 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
100MG | 获取报价 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称AZD-5153
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述AZD-5153 是一种有效、选择性、二价、口服的 BET/BRD4 溴结构域,IC50 为 5 nM。
-
产品描述AZD-5153 is a potent, selective, bivalent and orally available BET/BRD4 bromodomain with IC50 of 5 nM; simultaneously binds to two bromodomains in BRD4; exhibits antitumor activity in multiple xenograft models of acute myeloid leukemia, multiple myeloma, and diffuse large B cell lymphoma.Blood Cancer Phase 1 Clinical.
-
体外实验——
-
体内实验——
-
同义词AZD5153
-
通路Chromatin/Epigenetic
-
靶点Bromodomain
-
受体Bromodomain
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number1869912-39-9
-
分子量479.585
-
分子式C25H33N7O3
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCC1C(=O)N(CCN1CCOC2=CC=C(C=C2)C3CCN(CC3)C4=NN5C(=NN=C5OC)C=C4)C
-
化学全称(R)-4-(2-(4-(1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)-1,3-dimethylpiperazin-2-one
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Bradbury RH, et al. J Med Chem. 2016 Sep 8;59(17):7801-17.
2. Rhyasen GW, et al. Mol Cancer Ther. 2016 Nov;15(11):2563-2574.
3. Collins TA, et al. CPT Pharmacometrics Syst Pharmacol. 2017 Jun;6(6):357-364.